| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000648428 |
| P356 | DOI | 10.1007/BF00417473 |
| P698 | PubMed publication ID | 8032700 |
| P2093 | author name string | E Ballatori | |
| F Roila | |||
| M Tonato | |||
| A Del Favero | |||
| P2860 | cites work | Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting | Q70417884 |
| Vomiting induced by cyclophosphamide and phosphoramide mustard in cats | Q70424300 | ||
| Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide | Q70813642 | ||
| Extrapyramidal reactions with high-dose metoclopramide | Q71804122 | ||
| Antiemetics: neurotransmitter receptor binding predicts therapeutic actions | Q72524098 | ||
| High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy | Q93605950 | ||
| The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum | Q93608123 | ||
| Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial | Q93642117 | ||
| Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr | Q33190512 | ||
| Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron | Q33356839 | ||
| Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? | Q35181690 | ||
| 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret | Q35756396 | ||
| Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret | Q35981578 | ||
| Methodology of antiemetic trials: a review | Q37764625 | ||
| Pharmacological and anti-emetic properties of ondansetron. | Q38262032 | ||
| Neuropharmacology of emesis induced by anti-cancer therapy. | Q39583751 | ||
| Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group | Q40741060 | ||
| Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide | Q40754288 | ||
| Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial | Q41305280 | ||
| Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy | Q41769603 | ||
| Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. | Q43024600 | ||
| Publication of unethical studies on the treatment of chemotherapy-induced emesis | Q43667716 | ||
| Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. | Q44429257 | ||
| A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group | Q44495445 | ||
| A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy | Q44559396 | ||
| A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. | Q44569388 | ||
| Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. | Q44886671 | ||
| Methylprednisolone as an antiemetic drug. A randomised double blind study | Q49057183 | ||
| Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study | Q49069510 | ||
| Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis | Q51720893 | ||
| Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re | Q51746449 | ||
| Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. | Q51831525 | ||
| Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | Q52612776 | ||
| A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. | Q53405351 | ||
| Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. | Q53708801 | ||
| Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting | Q53730507 | ||
| Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial. | Q53745789 | ||
| Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. | Q55054035 | ||
| The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. | Q55060789 | ||
| On the receiving end--patient perception of the side-effects of cancer chemotherapy. | Q55062718 | ||
| Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. | Q55420286 | ||
| Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy | Q61868395 | ||
| ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS | Q61868401 | ||
| Effective Control of CMF-Related Emesis with High-Dose Dexamethasone | Q61900657 | ||
| Ondansetron and chest pain | Q67522201 | ||
| Serotonin antagonist antiemetics: progress and concerns | Q67592410 | ||
| Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure | Q67592423 | ||
| Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting | Q67594859 | ||
| Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy | Q67697225 | ||
| Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research | Q67883137 | ||
| A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy | Q67898658 | ||
| Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy | Q67899919 | ||
| Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone | Q67900841 | ||
| Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy | Q67901472 | ||
| Oral treatment with ondansetron in an outpatient setting | Q67902077 | ||
| Extrapyramidal reaction caused by ondansetron | Q67903312 | ||
| High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study | Q68159297 | ||
| Methylprednisolone for the control of CMF-induced emesis | Q68159301 | ||
| Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis | Q68252503 | ||
| Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy | Q68412436 | ||
| Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis | Q68435561 | ||
| A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group | Q68478567 | ||
| A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group | Q68478575 | ||
| Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group | Q68478579 | ||
| Methylprednisolone versus Metoclopramide for Prevention of Nausea and Vomiting in Breast Cancer Patients Treated with Intravenous Cyclophosphamide Methotrexate 5-Fluorouracil: A Double-Blind Randomized Study | Q68493429 | ||
| Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial | Q68950854 | ||
| Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial | Q69056837 | ||
| Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin | Q69291980 | ||
| GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting | Q69299648 | ||
| GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis | Q69300253 | ||
| Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone | Q69485750 | ||
| The effect of administration rate on cisplatin-induced emesis | Q69886663 | ||
| Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research | Q69921477 | ||
| Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis | Q69928199 | ||
| Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy | Q70051225 | ||
| The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting | Q70063203 | ||
| Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting | Q70177918 | ||
| A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy | Q70239642 | ||
| Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy | Q70370019 | ||
| The course of nausea and vomiting after high-dose cyclophosphamide | Q70395882 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 150-160 | |
| P577 | publication date | 1994-05-01 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Antiemetics in cancer chemotherapy: historical perspective and current state of the art. | |
| P478 | volume | 2 |
| Q44288290 | The effect of electroacupuncture as an adjunct on cyclophosphamide-induced emesis in ferrets | cites work | P2860 |
Search more.